Clopidogrel Tablet, Film Coated
Product Images NDC 0904-6467

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 0904-6467). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

4f439153 055d 4c05 B7f9 De8d4263d739 00

Clopidogrel tablets, USP 300 mg oral film-coated tablets unit dose by Major Pharmaceuticals. The label displays the product name, strength, form, NDC number 0904-6467-07, and specifies 30 tablets per package. It includes storage instructions and a pharmacist dispensing note to provide the medication guide. Distribution and manufacturing locations are noted along with a barcode at the bottom.*

FDA Label Image

Figure3

A forest plot depicting hazard ratios with 95% confidence intervals for various patient baseline characteristics and concomitant medications/interventions in the CURE study comparing Clopidogrel versus placebo. Subgroups include age groups, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, and previous stroke, showing the favorability of Clopidogrel relative to placebo across these variables.*

FDA Label Image

Figure3b

A forest plot illustrating hazard ratios with 95% confidence intervals for various patient baseline characteristics and on-study medications in the CURE study. It compares the effect of Clopidogrel versus placebo across subgroups including Heparin/LMWH use, Aspirin dose categories, GP IIb/IIIa antagonists, Beta-Blocker use, and ACE Inhibitor use, showing patient numbers and event percentages for each subgroup.*

FDA Label Image

Figure6

A forest plot chart titled 'Effects of Adding Clopidogrel to Aspirin on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups for the COMMIT Study.' It displays odds ratios with 99% confidence intervals for various subgroups including gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use, comparing Clopidogrel versus placebo outcomes.*

FDA Label Image

Figure7

A line graph titled 'Fatal or Non-Fatal Vascular Events in the CAPRIE Study' showing cumulative event rates (%) over months of follow-up (0 to 36 months). It compares event rates for Aspirin and Clopidogrel, with Aspirin's rate slightly higher throughout the study. The graph includes a p-value of 0.045 indicating statistical comparison.*

FDA Label Image

Figure8

A forest plot showing hazard ratios and 95% confidence intervals by baseline subgroups in the CAPRIE study comparing clopidogrel and aspirin. Subgroups include Stroke, MI, PAD, and Overall, with numerical values for patient counts and event percentages on both treatments. The horizontal axis ranges from 0.6 to 1.3 hazard ratio, indicating which treatment is favored.*

FDA Label Image

Clopiodgrel 01

Chemical structure diagram of clopidogrel bisulfate showing its molecular framework, including a chlorophenyl group, a thiophene ring, and the sulfate component indicated by H2SO4.*

FDA Label Image

Figure 01

A figure showing the effect of various proton pump inhibitors (PPIs) on the exposure to clopidogrel active metabolite following multiple doses of clopidogrel 75 mg. The chart compares changes in active metabolite AUC relative to clopidogrel administered alone, with data points and confidence intervals plotted for dexlansoprazole 60 mg, lansoprazole 30 mg, pantoprazole 80 mg, and omeprazole 80 mg.*

FDA Label Image

Figure2

A line graph titled 'Cardiovascular Death, Myocardial Infarction, and Stroke in the CURE Study' showing cumulative event rates (%) over 12 months of follow-up. Two curves compare placebo (+ aspirin) and clopidogrel (+ aspirin), with clopidogrel showing a lower event rate. The graph includes a p-value of 0.00009 and a note indicating other standard therapies were used as appropriate.*

FDA Label Image

Figure4

A cumulative event rate graph for death from the COMMIT study showing two curves, one for Placebo and one for Clopidogrel. The y-axis represents the percentage dead before first discharge, ranging from 0% to 9%, and the x-axis shows days since randomization, from 0 to 28 days. The Placebo group shows 8.1% deaths, and the Clopidogrel group shows 7.5% deaths, indicating a 7% proportional risk reduction (p=0.03).*

FDA Label Image

Figure5

A line chart titled 'Cumulative Event Rates for the Combined Endpoint Re-Infarction, Stroke or Death in the COMMIT Study' showing percentage with these events before first discharge over up to 28 days. Two lines compare placebo (10.1% event rate) and clopidogrel (9.2% event rate), indicating a 9% proportional risk reduction with clopidogrel. The x-axis is labeled 'Days since randomization,' and the y-axis shows percentage with event.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.